The Form 144 is a routine advance notice of a planned insider sale under a pre-existing 10b5-1 plan. No material impact expected. Monitor for actual execution on Form 4, but the small size and pre-planned nature suggest no negative signal.
Price Chart
Executive Summary
Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven Therapeutics (ELVN), with an estimated aggregate market value of $709,800. The sale is planned under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the insider established the plan months before this filing and is not acting on recent material non-public information. Given the small relative size of the proposed sale (approximately 0.03% of the $2.2B market cap) and the pre-planned nature, this filing is routine and unlikely to materially impact the stock.
Key Facts
- Board member Lori Anne Kunkel filed Form 144 to sell 20,000 shares of ELVN common stock.
- Estimated aggregate market value of the proposed sale is $709,800.
- Sale is to be executed under a Rule 10b5-1 trading plan adopted on March 6, 2026.
- Shares were acquired pre-IPO on March 12, 2020, as 'Pre-IPO Shares'.
- Proposed sale represents approximately 0.03% of ELVN's $2.2B market cap.
Financial Impact
Proposed sale of 20,000 shares worth approximately $709,800, representing a small fraction of the company's $2.2B market cap.
Risk Factors
- Insider sale could be perceived negatively by retail investors despite the 10b5-1 plan.
- If the company's stock price weakens ahead of the sale, the plan may still execute, adding modest sell pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001974158-26-000072 |
| Document: 0001974158-26-000072-index.html | 0001974158-26-000072 |
| Document: 0001974158-26-000072.txt | 0001974158-26-000072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.52 (−0.98%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $41.52 (+0.65%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $41.52 (+7.29%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.52 (+5.57%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.52 (−13.84%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.52 (−30.01%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.52 (−29.59%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.52 (−30.12%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.52 (−21.44%) |
Jun 22, 2026 18w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.52 (−14.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers